BioAge Labs Inc.

Last updated September 27, 2026

Organization details

Legal name
BioAge Labs Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Emeryville
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
BIOA
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001709941
EIN
47-4721157

Board of directors

Chief executives

Kristen Fortney · Chief Executive Officer
Since September 2024

Director election results

Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

6 of this board's directors also sit on 17 other boards.

Network of BioAge Labs Inc.'s board connections ALX Oncology Holdings Inc. ALX Oncology Holdings... ArriVent BioPharma Inc. ArriVent BioPharma Inc... Bolt Biotherapeutics Inc. Bolt Biotherapeutics I... Carrier Global Corporation Carrier Global Corpora... Jazz Pharmaceuticals plc Jazz Pharmaceuticals p... LB Pharmaceuticals Inc LB Pharmaceuticals Inc MaxCyte Inc. MaxCyte Inc. Natera Inc. Natera Inc. Nautilus Biotechnology Inc. Nautilus Biotechnology... NewAmsterdam Pharma Company N.V. NewAmsterdam Pharma Co... Rapport Therapeutics Inc. Rapport Therapeutics I... Seaport Therapeutics Inc. Seaport Therapeutics I... Silence Therapeutics Plc American Depository Share Silence Therapeutics P... Tenax Therapeutics Inc. Tenax Therapeutics Inc... Vera Therapeutics Inc. Vera Therapeutics Inc. Veradermics Incorporated Veradermics Incorporat... James Healy James Healy Jean Pierre Garnier Jean Pierre Garnier Michael H. Davidson Michael H. Davidson Patrick G. Enright Patrick G. Enright Rekha Hemrajani Rekha Hemrajani Vijay Satyanand Pande Vijay Satyanand Pand... BioAge Labs Inc.
Shared director Other board Same sector +1 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$7,793,412
13 sales by 4 insiders
Date Insider Transaction Shares Price Value
Jun 30, 2026 Barton Shane Officer (Principal Accounting Officer) Option exercise +4,290 $10.85 $46,547
Jun 30, 2026 Barton Shane Officer (Principal Accounting Officer) Option exercise +4,000 $8.39 $33,560
Jun 30, 2026 Barton Shane Officer (Principal Accounting Officer) Option exercise +4,065 $4.30 $17,480
Jun 30, 2026 Barton Shane Officer (Principal Accounting Officer) Option exercise +7,861 $4.38 $34,431
Jun 30, 2026 Barton Shane Officer (Principal Accounting Officer) Open-market sale −20,216 $25.19 $509,176
Jun 29, 2026 Barton Shane Officer (Principal Accounting Officer) Option exercise +9,301 $10.85 $100,916
Jun 29, 2026 Barton Shane Officer (Principal Accounting Officer) Option exercise +7,261 $8.39 $60,920
Jun 29, 2026 Barton Shane Officer (Principal Accounting Officer) Option exercise +8,958 $4.30 $38,519
Jun 29, 2026 Barton Shane Officer (Principal Accounting Officer) Option exercise +14,198 $4.38 $62,187
Jun 29, 2026 Barton Shane Officer (Principal Accounting Officer) Open-market sale −42,350 $25.21 $1,067,576
Apr 23, 2026 Dov A. Goldstein M.D. Officer (Chief Financial Officer) Option exercise +3,542 $4.38 $15,514
Apr 1, 2026 RUBIN PAUL D Officer (Chief Medical Officer) Option exercise +5,437 $4.11 $22,346
Apr 1, 2026 RUBIN PAUL D Officer (Chief Medical Officer) Option exercise +3,383 $6.57 $22,226
Apr 1, 2026 RUBIN PAUL D Officer (Chief Medical Officer) Open-market sale −8,820 $17.81 $157,084
Mar 2, 2026 RUBIN PAUL D Officer (Chief Medical Officer) Option exercise +5,433 $4.11 $22,330

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.